|
|
Volumn 9, Issue 9, 2013, Pages 2017-2018
|
|
Cancer vaccines in the immunotherapy era : Rational approach
a
|
|
Author keywords
Cancer vaccine; Combination therapy; Immunology; Tumor associated antigen; Vaccine congress
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
B7 ANTIGEN;
CANCER VACCINE;
EPITOPE;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE;
INTERCELLULAR ADHESION MOLECULE 1;
LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;
MONTANIDE ISA 51;
MUCIN 1;
PLACEBO;
PROSTATE SPECIFIC ANTIGEN;
SURVAXM;
TOLL LIKE RECEPTOR 2 AGONIST;
TOLL LIKE RECEPTOR AGONIST;
UNCLASSIFIED DRUG;
ANTIGEN PRESENTING CELL;
B7 1 GENE;
BREAST TUMOR;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNIZATION;
CANCER PREVENTION;
CASTRATION RESISTANT PROSTATE CANCER;
CELL MEDIATED CYTOTOXICITY;
CELLULAR IMMUNITY;
CONFERENCE PAPER;
GLIOBLASTOMA;
HUMAN;
ICAM 1 GENE;
LFA3 GENE;
NONHUMAN;
PROSTATE SPECIFIC ANTIGEN GENE;
SURVIVAL RATE;
T LYMPHOCYTE ACTIVATION;
TUMOR GENE;
CANCER VACCINE;
COMBINATION THERAPY;
IMMUNOLOGY;
TUMOR ASSOCIATED ANTIGEN;
VACCINE CONGRESS;
CANCER VACCINES;
COMBINED MODALITY THERAPY;
HUMANS;
IMMUNOTHERAPY;
NEOPLASMS;
T-LYMPHOCYTES;
|
|
EID: 84884604019
PISSN: 21645515
EISSN: 2164554X
Source Type: Journal
DOI: 10.4161/hv.25556 Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (3)
|
